Kymera Therapeutics Inc. has described salts of IL-1 receptor-associated kinase 4 (IRAK-4) degradation inducers and their crystalline forms reported to be useful for the treatment of autoimmune diseases and inflammatory disorders.
Scientists at Centre Hospitalier Regional Universitaire de Lille, INSERM and University of Lille have divulged diphenylpyrazole compounds acting as β-amyloid (Aβ) production inhibitors and autophagy marker ratio modulators reported to be useful for the treatment of Alzheimer’s disease.
Sanwa Kagaku Kenkyusho Co. Ltd. has synthesized imidazole derivatives acting as α1A-adrenoceptor agonists reported to be useful for the treatment of orthostatic hypotension and urinary incontinence.
Appicine Therapeutics (HK) Ltd. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising a E3 ubiquitin ligase-binding moiety coupled to a Bcl-2-like protein 1 (Bcl-xL; Bcl-X; BCL2L1)-targeting moiety through a linker. They are reported to be useful for the treatment of cancer.
Researchers from Gempharmatech Co. Ltd. presented a new humanized mouse model for preclinical research into the functionality and therapeutic potential of IL-12.
Bioatla Inc. has received FDA clearance of its IND application for BA-3361, a conditionally active biologic (CAB)-Nectin-4 antibody-drug conjugate (ADC) for the treatment of multiple tumor types.
Researchers from ADC Therapeutics SA presented the discovery and preclinical evaluation of a novel camptothecin-based Claudin-6-specific antibody-drug conjugate (ADC), GB01-VA-PL2202.
Lantern Pharma Inc. has entered into a strategic artificial intelligence (AI)-driven collaboration with Oregon Therapeutics SAS to optimize the development of Oregon’s first-in-class protein disulfide isomerase (PDI) inhibitor drug candidate XCE-853 in novel and targeted cancer indications.
MicroRNAs (miRNAs) are small noncoding RNAs that play important roles in immune response regulation in autoimmune disease such as autoimmune hepatitis. Researchers investigated whether Δ8-tetrahydrocannabinol (THC), which is present in marijuana, could prevent the development of autoimmune hepatitis in treated mice by altering miRNA expression.
RSS
